Background
New vaccine strategies against HIV should induce protective mucosal immune response in the female genital tract which is a first site of virus acquisition. The microbiome has been implicated in altered mucosal immunity, but its impact on vaccine-induced mucosal responses in the genital tract is not well understood.
Methods
Cervicovaginal mucus samples were collected from participants (n=95) receiving the RV144 ALVAC-HIV/AIDSVAX B/E prime/boost vaccine regimen followed by a late boost with ALVAC-HIV and/or AIDSVAX B/E. Vaginal microbiome data was generated by shogtun metagenomic sequencing, and label-free tandem mass spectrometry generated data in mucus on human and microbial proteins. Mucosal and serum BAb levels were measured using ELISA. Linear models were used to analyze relationships between the microbiome, host proteome, and vaccine immune responses.
Results
Participants clustered into 3 microbiome groups: Lactobacillus (L.) crispatus dominant (n=20, 21.1%), L. iners dominant (n=40, 42.1%) and a polymicrobial group (PM, n=36.8, 36.8%). Relative to the L. crispatus group, women with a PM microbiome showed increased activation of pathways involved in B and T cell receptor signaling, MHC class I/II antigen presentation, and neutrophil degranulation (Z score>5; P<0.0001). Women with a consistent LD biome across all time-points showed significantly higher BAb levels compared to consistent nLD women at 2 weeks post-RV144 regimen, including those in the mucosa against A244 (IgG-gp120A244gD-D11, P=0.0393), and in serum (IgG-gp70E, P=0.004; IgG-A244-D11, P=0.0153). Linear models associated Lactobacillus spp. with BAb levels in mucus and serum (P<0.01) as well as > 100 human proteins. Two mucosal proteins significantly associated (FDR< 0.02) with both LD microbiomes and antibody responses, including LRRFIP1, which is involved in TLR signaling. Biological pathways involved in innate immunity and antigen presentation associated with both high vaccine response and LD microbiomes, including TGFb signaling, IL-4 signaling, the MHC pathway, elevated cytosolic Ca2+ response, and neutrophil degranulation pathway.
Conclusions
These data suggest an association between the vaginal microbiome and innate immunity, with a more inflammatory polymicrobial environment being associated with lower vaccine-specific BAb levels. These results warrant further interrogations of potential mechanisms by which the vaginal microbiome may impact vaccine responses and could inform interventional strategies.